Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Emergence of Highly-Plastic B Cell States Cooperates with Early Immune Microenvironment Remodeling to Drive Follicular Lymphomagenesis

Blood (2023) 142 (Supplement 1): 717.

https://doi.org/10.1182/blood-2023-185829

Published: 2023

Journal Articles

Iberdomide Enhances Dara Mediated Cytotoxicity through Upregulation of CDC Activity and Elevated NK Cell Mediated ADCC

Peilin Ma, Vinidhra Sridharan, Krista Wollerman, Debjani Dutta, Ram Kumar Singh, Sambuddo Mukherjee, Chad C. Bjorklund, Patrick R Hagner, Michael Amatangelo, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 3289.

https://doi.org/10.1182/blood-2023-189423

Published: 2023

Journal Articles

Fedratinib Overcomes Ruxolitinib Resistance through Inhibition of the Interferon Signaling Pathway

Danny Jeyaraju, Ann Polonskaia, Chih-Chao Hsu, Patrick R Hagner, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 1434.

https://doi.org/10.1182/blood-2023-181898

Published: 2023

Journal Articles

Mezigdomide Reverses T-Cell Exhaustion through Degradation of Aiolos/Ikaros and Reinvigoration of Cytokine Production Pathways

Hsiling Chiu, Junfei Zhao, Maria Ortiz Estevez, Patrick R Hagner, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 335.

https://doi.org/10.1182/blood-2023-189445

Published: 2023

Journal Articles

Celmod Induced Disruption of Granulopoiesis Continuum Identified Using Humanized Cereblon Mice

Ajit Dhadve, Neelam Kumari, Amrutha Y, Riddhita Deb, Gobinathan Rengarasu, Ramya V, Swetha Muralidhar, Shwetank Verma, Patrick R Hagner, Sambuddo Mukherjee, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 5586.

https://doi.org/10.1182/blood-2023-189539

Published: 2023

Journal Articles

Investigation of the Synergistic Combination of a Novel Celmod (CC-99282) and BET Inhibitors in Preclinical DLBCL

Chih-Chao Hsu, Hsiling Chiu, Chad C. Bjorklund, Patrick R Hagner, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 5719.

https://doi.org/10.1182/blood-2023-189191

Published: 2023

Journal Articles

A Multiomic Single-Cell Atlas of Human Myelopoiesis Reveals Cellular and Molecular Drivers of Immunomodulatory Drug-Induced Neutropenia

Christina Simoglou Karali, Simone Riva, Sally-Ann Clark, Sean Wen, Nikolaos Sousos, Eleni Louka, E. Ravza Gür, Nawshad Hayder, William E. Pierceall, Anjan Thakurta, Anita K. Gandhi, Patrick R Hagner, Jim Hughes, Adam J Mead

Blood (2023) 142 (Supplement 1): 935.

https://doi.org/10.1182/blood-2023-182041

Published: 2023

Journal Articles

Differential Chromatin Organization between t(4;14) and Non-t(4;14) Multiple Myeloma Driven By the Histone Methyltransferase NSD2

Chad C. Bjorklund, Junfei Zhao, Gaurav Jain, Natasha Shtraizent, Maria Ortiz, Sambuddo Mukherjee, Patrick R Hagner, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 3295.

https://doi.org/10.1182/blood-2023-190137

Published: 2023

Journal Articles

Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1

Blood (2022) 139 (13): 2024–2037.

https://doi.org/10.1182/blood.2021014701

Published: 2022

Includes: Supplemental data

Journal Articles

Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy

Blood (2021) 137 (2): 216–231.

https://doi.org/10.1182/blood.2020006073

Published: 2021

Includes: Supplemental data

Journal Articles

Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent

Alberto Risueño, Patrick R. Hagner, Fadi Towfic, Celia Fontanillo, Amira Djebbari, Joel S. Parker, Clifton P. Drew, Grzegorz S. Nowakowski, Matthew J. Maurer, James R. Cerhan, Xin Wei, Yan Ren, Chung-Wein Lee, Suzana Couto, Maria Wang, Michael Pourdehnad, Anita K. Gandhi, Matthew W. B. Trotter

Blood (2020) 135 (13): 1008–1018.

https://doi.org/10.1182/blood.2019002414

Published: 2020

Includes: Supplemental data

Journal Articles

Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier

Blood (2020) 135 (13): 996–1007.

https://doi.org/10.1182/blood.2019002395

Published: 2020

Includes: Supplemental data

Journal Articles

Targeting B-Cell Maturation Antigen (BCMA) with CC-93269, a 2+1 T Cell Engager, Elicits Significant Apoptosis in Diffuse Large B-Cell Lymphoma Preclinical Models

Patrick R. Hagner, PhD, Michelle Waldman, MS, Falon D. Gray, DVM, DACVP, Renee Yura, PhD, Sarah Hersey, MS, MBA, Henry Chan, PhD, Mingjun Zhang, PhD, Isaac Boss, Anita K Gandhi

Blood (2019) 134 (Supplement_1): 1580.

https://doi.org/10.1182/blood-2019-126115

Published: 2019

Journal Articles

Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma

Blood (2019) 134 (Supplement_1): 919.

https://doi.org/10.1182/blood-2019-123694

Published: 2019

Journal Articles

Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse

Blood (2019) 134 (Supplement_1): 923.

https://doi.org/10.1182/blood-2019-122756

Published: 2019

Journal Articles

Interactome of Aiolos/Ikaros in Diffuse Large B-Cell Lymphoma (DLBCL) Reveals Novel Combination of Cereblon Modulators (CELMoD) and Histone Deacetylase (HDAC) Inhibitors

Patrick R. Hagner, PhD, Hsiling Chiu, MS, Vivek S. Chopra, PhD, Martino S. Colombo, PhD, Nisha Patel, PhD, Maria Ortiz, Remco S. Loos, PhD, Fadi Towfic, PhD, Michelle Waldman, MS, Anita K Gandhi

Blood (2019) 134 (Supplement_1): 306.

https://doi.org/10.1182/blood-2019-126681

Published: 2019

Journal Articles

Profiling the Immune Tumor Microenvironment of Newly Diagnosed Diffuse Large B Cell Lymphoma Identifies Three Major Immune Infiltration Patterns

C. Chris Huang, PhD, Yumi Nakayama, PhD, Matthew Stokes, PhD, Fadi Towfic, PhD, chung-Wein Lee, Yan Ren, Mathieu Marella, PhD, Maria Wang, Patrick R. Hagner, PhD, Suzana Couto, Kathryn Newhall, Anita K Gandhi

Blood (2019) 134 (Supplement_1): 2797.

https://doi.org/10.1182/blood-2019-123691

Published: 2019

Journal Articles

Eliciting Anti-Tumor T Cell Immunity in Chronic Lymphocytic Leukemia (CLL) with PD-L1/PD-1 Blockade Is Enhanced By Avadomide Immunotherapy through the Triggering of Immunogenic Interferon Signaling

Nikolaos Ioannou, PhD MSc, BSc, Patrick R. Hagner, PhD, Fadi Towfic, PhD, Anita K. Gandhi, PhD, Kostas Stamatopoulos, MD PhD, Piers E.M. Patten, BSc, MRCP, MRCPath, PhD, Anna Vardi, MD PhD, Alan G. Ramsay, BSc,MSc,PhD

Blood (2018) 132 (Supplement 1): 237.

https://doi.org/10.1182/blood-2018-99-111605

Published: 2018

Journal Articles

Mechanism of Synergistic Effects on T Cell Activation By Avadomide (CC-122) and Nivolumab

Yumi Nakayama, PhD, Matthew E. Stokes, PhD, Michelle Waldman, MS, Patrick R. Hagner, PhD, Anita K. Gandhi, PhD

Blood (2018) 132 (Supplement 1): 4133.

https://doi.org/10.1182/blood-2018-99-114469

Published: 2018

Journal Articles

Avadomide (CC-122) Alters T Cell Repertoire and Enhances Infiltration of Lymphocytes into Tumor Microenvironment in DLBCL Patients

Patrick R. Hagner, PhD, Fadi Towfic, PhD, Frank Schmitz, MD PhD, Xuehai Wang, PhD, Andrew P. Weng, MD, Michael Pourdehnad, MD, Anita K. Gandhi, PhD

Blood (2018) 132 (Supplement 1): 4211.

https://doi.org/10.1182/blood-2018-99-114481

Published: 2018

NARROW

Emergence of Highly-Plastic B Cell States Cooperates with Early Immune Microenvironment Remodeling to Drive Follicular Lymphomagenesis

Iberdomide Enhances Dara Mediated Cytotoxicity through Upregulation of CDC Activity and Elevated NK Cell Mediated ADCC

Fedratinib Overcomes Ruxolitinib Resistance through Inhibition of the Interferon Signaling Pathway

Mezigdomide Reverses T-Cell Exhaustion through Degradation of Aiolos/Ikaros and Reinvigoration of Cytokine Production Pathways

Celmod Induced Disruption of Granulopoiesis Continuum Identified Using Humanized Cereblon Mice

Investigation of the Synergistic Combination of a Novel Celmod (CC-99282) and BET Inhibitors in Preclinical DLBCL

A Multiomic Single-Cell Atlas of Human Myelopoiesis Reveals Cellular and Molecular Drivers of Immunomodulatory Drug-Induced Neutropenia

Differential Chromatin Organization between t(4;14) and Non-t(4;14) Multiple Myeloma Driven By the Histone Methyltransferase NSD2

Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1

Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy

Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent

Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier

Targeting B-Cell Maturation Antigen (BCMA) with CC-93269, a 2+1 T Cell Engager, Elicits Significant Apoptosis in Diffuse Large B-Cell Lymphoma Preclinical Models

Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma

Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse

Interactome of Aiolos/Ikaros in Diffuse Large B-Cell Lymphoma (DLBCL) Reveals Novel Combination of Cereblon Modulators (CELMoD) and Histone Deacetylase (HDAC) Inhibitors

Profiling the Immune Tumor Microenvironment of Newly Diagnosed Diffuse Large B Cell Lymphoma Identifies Three Major Immune Infiltration Patterns

Eliciting Anti-Tumor T Cell Immunity in Chronic Lymphocytic Leukemia (CLL) with PD-L1/PD-1 Blockade Is Enhanced By Avadomide Immunotherapy through the Triggering of Immunogenic Interferon Signaling

Mechanism of Synergistic Effects on T Cell Activation By Avadomide (CC-122) and Nivolumab

Avadomide (CC-122) Alters T Cell Repertoire and Enhances Infiltration of Lymphocytes into Tumor Microenvironment in DLBCL Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only